Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dovato in ART-naive adolescents with HIV-1
2025-000361-93Phase 3
- Sponsor
- ViiV Healthcare
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dolutegravir + lamivudine, dolutegravir and lamivudine in Human immunodeficiency virus infection type 1, sponsored by ViiV Healthcare. Primary endpoint: Proportion with plasma HIV-1 RNA <50 copies/mL at Week 48.
02
Drugs
dolutegravir + lamivudinedolutegravirlamivudine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2025-000361-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-000361-93.